SubHero Banner

Xpovio® (selinexor) – New indication

June 22, 2020 - Karyopharm Therapeutics announced the FDA approval of Xpovio (selinexor), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Download PDF